M. C. Miranda

Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV

This study develops MERS-CoV vaccines using a protein nanoparticle platform, showing they induce strong neutralizing antibodies and protect mice against MERS-CoV challenge.

De novo design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8

This paper designs highly selective miniprotein inhibitors for integrins αvβ6 and αvβ8 with picomolar affinity and therapeutic potential in a mouse fibrosis model.

Computational design of non-porous, pH-responsive antibody nanoparticles

This paper designs pH-responsive antibody nanoparticles with three distinct protein components that disassemble at tunable pH levels, enabling targeted delivery of biologics.

Precisely patterned nanofibers made from extendable protein multiplexes

The paper designs extendable protein multiplexes with symmetric architectures to create precisely patterned nanofibers through controlled repeat propagation and hydrophilic patch placement.

Improving the secretion of designed protein assemblies through negative design of cryptic transmembrane domains

This study identifies cryptic transmembrane domains in designed protein nanoparticles that hinder secretion and introduces a computational tool, Degreaser, to remove them while maintaining stability, improving secretion efficiency.

Durable protection against SARS-CoV-2 Omicron induced by an adjuvanted subunit vaccine

This study shows that an adjuvanted subunit vaccine provides durable protection against SARS-CoV-2 Omicron in non-human primates, with strong neutralizing antibodies and memory T/B cells after booster doses.

Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice

This study compares neutralizing antibody responses to SARS-CoV-2 variants in vaccinated humans and mice, finding that mice do not accurately reflect the breadth and potency seen in humans.

Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants

This study investigates how delta and kappa SARS-CoV-2 variants evade immune responses by altering antigenic sites and reducing ACE2 binding affinity.

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

This study shows that a SARS-CoV-2 RBD nanoparticle vaccine protects against SARS-CoV-2 and related sarbecoviruses, including variants, in mice and non-human primates.

Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates

This study evaluates adjuvants for a subunit SARS-CoV-2 nanoparticle vaccine in non-human primates, showing durable neutralizing antibody responses and protection against infection.

Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2

This study designs SARS-CoV-2 nanoparticle vaccines that induce strong neutralizing antibodies in mice, with higher titers and lower doses than existing trimer vaccines.